{"entity":{"id":"nct05236972","kind":"trial","name":"PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of sintilimab, fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Sun Yat-sen University, now recruiting.","summary":"PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05236972 by Sun Yat-sen University, with a registry enrolment figure of 323 participants, started 2022-01-01 and due to reach its primary completion in 2026-06-01. Interventions recorded: Sintilimab; Oxaliplatin; capecitabine. Conditions listed: Colorectal Carcinoma. Primary outcome: Disease Free survival [ Time Frame: 3 years ]. Colorectal eligibility wording from the registry: \", any T, N1 or N2, M0) adenocarcinoma of the colon (as defined by the presence of the inferior pole of the tumour above the peritoneal reflection - that is, at least 10 cm from the anal margin)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05236972","url":"https://clinicaltrials.gov/study/NCT05236972"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["sintilimab","folfox","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05236972","phase":"3","setting":"Study of Sintilimab vs Standard Therapy in Participants With Mismatch Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Stage III Colorectal Cancer","sponsor":"Sun Yat-sen University","enrolled":323,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05236972/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}